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Background: OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal
doxorubicin (PLD; CentoCor Ortho Biotech Products L.P., Raritan, NJ, USA). over single-agent PLD in 672 patients
with relapsed ovarian cancer, particularly in the partially platinum-sensitive subgroup [platinum-free interval (PFI) of 6–
12 months]. This superiority has been suggested to be due to the differential impact of subsequent (platinum) therapy.
Patients and methods: A detailed analysis of subsequent therapies and survival outcomes in the overall population
and in the subsets according to platinum sensitivity was therefore conducted.
Results: Similar proportions of patients received subsequent therapy in each arm (76% versus 77%), including further
platinum-based regimens (49% versus 55%). Patients in the trabectedin/PLD arm received subsequent chemotherapy
at a later time (median delay 2.5 months versus PLD arm). Overall survival from subsequent platinum was signiﬁcantly
prolonged in the partially platinum-sensitive disease subset (hazard ratio = 0.63; P = 0.0357).
Conclusion: The superiority of trabectedin/PLD over single-agent PLD in OVA-301 cannot be explained by
differences in the extent or nature of subsequent therapies administered to these patients. On the other hand, these
exploratory analyses support the hypothesis that the enhanced survival beneﬁts in the partially platinum-sensitive
subset might be due to an extended PFI leading to longer survival with subsequent platinum.
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introduction
Trabectedin is a marine-derived antineoplastic agent ﬁrst
isolated from the tunicate Ecteinascidia turbinata and currently
produced synthetically, which has shown in vitro and in vivo
activity in multiple tumor types, including soft tissue sarcoma
(STS) [1–4] and ovarian cancer [5–7]. Trabectedin was ﬁrst
approved as a single agent in the European Union in 2007 and,
subsequently, in many other countries worldwide for the
treatment of STS patients after failure of standard-of-care
chemotherapies. Trabectedin in combination with pegylated
liposomal doxorubicin (PLD) was approved in the European
Union in 2009 for the treatment of patients with relapsed,
platinum-sensitive ovarian cancer [8].
The basis for the label extension in ovarian cancer was mainly
the positive results of a large phase III trial (OVA-301), in
which 672 patients in relapse after initial platinum-based
chemotherapy were randomly assigned to receive either
trabectedin/PLD or PLD alone. The trial was stratiﬁed by
platinum sensitivity, with one-third of the patients having
platinum-resistant disease [i.e. platinum-free interval
(PFI) < 6 months] at baseline. Progression-free survival (PFS)
by independent radiology review was the primary end point
[9, 10]. When combined with PLD, trabectedin signiﬁcantly
prolonged PFS over PLD alone with acceptable tolerability, as
reﬂected by short-lived, noncumulative and predictable
toxicity, with no new or unexpected toxic effects. In the
platinum-sensitive stratum (PFI ‡ 6 months), the risk reduction
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0.73; P = 0.0170; median PFS 9.2 versus 7.5 months]. A protocol-
speciﬁed interim analysis of overall survival (OS) was conducted
with 300 events (versus 520 required for the ﬁnal OS analysis)
showing a 15% reduction in the risk of death with the
combination (HR = 0.85; P = 0.1506). An updated OS interim
analysis was conducted, at the request of regulatory authorities,
with an additional year of follow-up and 419 events, the results
of which have been presented elsewhere [8, 11, 12]. The updated
OS results conﬁrmed and strengthened those reported previously
in a more mature dataset (HR = 0.85; P = 0.092). A signiﬁcant
41% decrease in the risk of death was found in the partially
platinum subset (HR = 0.59; P = 0.0015) [12]. Median OS for the
partially platinum-sensitive subset was 23.0 months in the
trabectedin/PLD arm versus 17.1 months in the PLD arm
(median difference of 5.9 months). Importantly, for this
subgroup, this difference in median OS is greater than the
difference in median PFS (1.9 months).
In vitro and clinical data suggest that extension of PFI by
intercalation of a nonplatinum therapy before platinum
rechallenge may provide clinical beneﬁt, particularly in patients
with partially platinum-sensitive relapsed ovarian cancer
[13–17]. The current report evaluates the subsequent therapies
administered to OVA-301 patients after discontinuation of
protocol therapy and their potential effects on the OS of these
patients. Furthermore, the current hypothesis-generating
analyses evaluated whether enhanced survival beneﬁts with
trabectedin/PLD over PLD alone in this trial could be ascribed
Table 1. Summary of subsequent therapies (all randomized patients)
All randomized patients PLD
(n = 335),
n (%)
Trabectedin/
PLD (n = 337),
n (%)
Total
(N = 672),
n (%)
Any subsequent therapy
a 259 (77) 257 (76) 516 (77)
Chemotherapy 244 (73) 236 (70) 480 (71)
Platinum based 183 (55) 164 (49) 347 (52)
Nonplatinum based 61 (18) 72 (21) 133 (20)
Surgery (major
cytoreduction)
14 (4) 19 (6) 33 (5)
Biological/hormonal
therapy
30 (9) 32 (9) 62 (9)
Radiation therapy 14 (4) 24 (7) 38 (6)
Miscellaneous
b 9 (3) 6 (2) 15 (2)
Categories shown are not mutually exclusive (one patient could receive
more than one type of subsequent therapy) except for chemotherapy. For
example, 79% of patients who had surgery did also receive chemotherapy.
aA total of 156 patients did not receive subsequent therapy: 61 of them (28
in PLD arm and 33 in trabectedin/PLD arm) were alive at last follow-up.
bMostly experimental drugs.
PLD, pegylated liposomal doxorubicin.
Table 2. Summary of subsequent therapies (per platinum sensitivity subset)
Platinum-resistant subset (PFI < 6 months) PLD (n = 123),
n (%)
Trabectedin/PLD
(n = 119), n (%)
Total (N = 242),
n (%)
Any subsequent therapy 90 (73) 85 (71) 175 (72)
Chemotherapy 80 (65) 79 (66) 159 (66)
Platinum based 47 (38) 39 (33) 86 (36)
Nonplatinum based 33 (27) 40 (34) 73 (30)
Surgery (major cytoreduction) 4 (3) 9 (8) 13 (5)
Biological/hormonal therapy 11 (9) 9 (8) 20 (8)
Radiation therapy 4 (3) 9 (8) 13 (5)
Partially platinum-sensitive subset
(PFI 6–12 months)
PLD (n = 91),
n (%)
Trabectedin/PLD
(n = 123), n (%)
Total (N = 214),
n (%)
Any subsequent therapy 73 (80) 99 (80) 172 (80)
Chemotherapy 71 (78) 91 (74) 162 (76)
Platinum based 52 (57) 69 (56) 121 (57)
Nonplatinum based 19 (21) 22 (18) 41 (19)
Surgery (major cytoreduction) 1 (1) 2 (2) 3 (1)
Biological/hormonal therapy 9 (10) 19 (15) 28 (13)
Radiation therapy 3 (3) 5 (4) 8 (4)
Platinum-sensitive subset
(PFI >12 months)
PLD (n = 122),
n (%)
Trabectedin/PLD
(n = 95), n (%)
Total (N = 217),
n (%)
Any subsequent therapy 97 (80) 74 (78) 171 (79)
Chemotherapy 94 (77) 67 (71) 161 (74)
Platinum based 84 (69) 55 (58) 139 (64)
Nonplatinum based 10 (8) 12 (13) 22 (10)
Surgery (major cytoreduction) 9 (7) 8 (8) 17 (8)
Biological/hormonal therapy 10 (8) 4 (4) 14 (6)
Radiation therapy 7 (6) 10 (11) 17 (8)
Categories shown are not mutually exclusive (one patient could receive more than one type of subsequent therapy) except for chemotherapy.
PFI, platinum-free interval; PLD, pegylated liposomal doxorubicin.
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patients and methods
study design
Full details of OVA-301 trial and the key baseline characteristics of the
overall study population have been previously described in detail [10].
Brieﬂy, OVA-301 was an open-label, multicenter, randomized phase III
clinical trial that investigated the efﬁcacy and safety of PLD 30 mg/m
2
followed by trabectedin 1.1 mg/m
2 every 3 weeks compared with PLD
50 mg/m
2 every 4 weeks. Eligible patients were women ‡ 18 years old with
histologically proven epithelial ovarian, fallopian tube, or primary peritoneal
carcinoma in relapse or progression after one platinum-based chemotherapy
regimen. Patients with platinum-resistant (PFI < 6 months) or platinum-
sensitive disease (PFI ‡ 6 months) were eligible (the trial was stratiﬁed on this
basis). The primary end point was PFS by independent radiology assessment.
Secondary analyses of PFS were based on independent oncologist and
investigator’s assessments, and the trial was also powered for OS. From April
2005 to May 2007, 672 patients (335 for PLD and 337 for trabectedin/PLD)
were randomized. The ﬁnal PFS analysis was conducted with 389 events
assessed by independent radiology review in patients with radiologically
measurable disease with a predetermined data cut-off (15 May 2008) [10].
Cut-off for current analysis of subsequent therapies was 31 May 2009.
evaluation of subsequent therapies
Information on subsequent therapies administered to patients after
discontinuing protocol treatment included type and date of therapy. For
surgery, information on the procedure was collected. For subsequent
chemotherapy and other treatments, the agents’ or the procedure’s names
and dates of occurrence, but not the response or date of clinical/radiological
progression, were recorded. Therefore, this report is focused on the
description of subsequent therapies. An exploratory analysis of OS from the
beginning of subsequent treatment is also provided. Data are shown for the
overall population, for the protocol strata of patients with platinum-
resistant and platinum-sensitive disease, as well as for the clinically
important subset of patients with partially platinum-sensitive disease (i.e.
those with PFI 6–12 months), which represents an area of intense
controversy for the optimal treatment options and research [18, 19].
statistical methods
All randomized (intent-to-treat) patients were included in the different
analyses: overall population, platinum sensitivity strata per investigator
(platinum resistant and platinum sensitive), and by PFI subsets in the
platinum-sensitive stratum (6–12 months and >12 months). The variable
‘PFI’ at baseline was calculated as time between last dose of prior platinum
and progression before the start of protocol therapy (either PLD or
trabectedin/PLD). Therefore, a minor discrepancy can be found in the total
number of patients versus the investigator-based allocation to protocol
Table 3. Summary of any subsequent platinum-based chemotherapy (all randomized patients and per platinum sensitivity subset)
All randomized patients with subsequent platinum therapy PLD (n = 183), n (%) Trabectedin/PLD (n = 164), n (%) Total (n = 347)
Platinum based
a
Single agent 36 (20) 29 (18) 65 (19)
Combination
b 147 (80) 135 (82) 282 (81)
Platinum-resistant subset (PFI < 6 months) PLD (n = 47), n (%) Trabectedin/PLD (n = 39), n (%) Total (N = 86), n (%)
Platinum based
Single agent 9 (19) 4 (10) 13 (15)
Combination 38 (81) 35 (90) 73 (85)
Partially platinum-sensitive subset (PFI 6–12 months) PLD (n = 52) Trabectedin/PLD (n = 69) Total (N = 121),
Platinum based
Single agent 14 (27) 16 (23) 30 (25)
Combination 38 (73) 53 (77) 91 (75)
Platinum-sensitive subset (PFI >12 months) PLD (n = 84) Trabectedin/PLD (n = 55) Total (N = 139)
Platinum-based
Single agent 13 (15) 9 (16) 22 (16)
Combination 71 (85) 46 (84) 117 (84)
aPatients with subsequent platinum at different times (i.e., as ﬁrst, second or further lines) (see also Figure 1).
bCarboplatin/gemcitabine and carboplatin/paclitaxel were the most common.
PFI, platinum-free interval; PLD, pegylated liposomal doxorubicin.
Figure 1. Flow chart of patients receiving platinum as further
chemotherapy. PLD, pegylated liposomal doxorubicin.
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All randomized patients PLD (n = 335), n (%) Trabectedin/PLD (n = 337), n (%) Total (N = 672), n (%)
Platinum based
a
Single agent 26 (8) 15 (4) 41 (6)
Combination
b 122 (36) 100 (30) 222 (33)
Nonplatinum based
Single agent 72 (21) 82 (24) 154 (23)
Combination
c 6 (2) 7 (2) 13 (2)
Platinum-resistant subset (PFI < 6 months) PLD (n = 123), n (%) Trabectedin/PLD (n = 119), n (%) Total (N = 242), n (%)
Platinum based
Single agent 5 (4) 1 (1) 6 (2)
Combination 31 (25) 26 (22) 57 (24)
Nonplatinum based
Single agent 33 (27) 36 (30) 69 (29)
Combination 4 (3) 5 (4) 9 (4)
Partially platinum-sensitive subset (PFI 6–12 months) PLD (n = 91), n (%) Trabectedin/PLD (n = 123), n (%) Total (N = 214), n (%)
Platinum based
Single agent 11 (12) 9 (7) 20 (9)
Combination 34 (37) 40 (33) 74 (35)
Nonplatinum based
Single agent 24 (26) 32 (26) 56 (26)
Combination — 2 (2) 2 (1)
Platinum-sensitive subset (PFI >12 months) PLD (n = 122), n (%) Trabectedin/PLD (n = 95), n (%) Total (N = 217), n (%)
Platinum based
Single agent 10 (8) 5 (5) 15 (7)
Combination 58 (48) 34 (36) 92 (42)
Nonplatinum based
Single agent 16 (13) 16 (17) 32 (15)
Combination 1 (1) — 1 (<1)
aPatients with subsequent platinum as ﬁrst line (see also Figure 1).
bCarboplatin/gemcitabine and carboplatin/paclitaxel were the most common regimens.
cTaxanes (docetaxel and paclitaxel) and topotecan were the most frequent agents in nonplatinum-based combinations
PFI, platinum-free interval; PLD, pegylated liposomal doxorubicin.
Figure 2. Percentage of patients receiving subsequent platinum therapies per platinum-free interval. PFI, platinum-free interval (P < 0.0001).
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Kaplan–Meier method. Hazard ratios from Cox regressions and treatment
arms were compared by the log-rank test. A linear regression was
performed to calculate the slope for the percentage of patients receiving
platinum therapy according to their PFI at baseline.
results
subsequent therapies
all randomized patients. As of the 31 May 2009 cut-off, 77% of
patients treated in OVA-301 had received subsequent therapy
after completing either PLD alone or trabectedin/PLD
(Table 1). At the time of this analysis, subsequent
chemotherapy was received by 71% of patients, which included
subsequent platinum-based chemotherapy for 52% of patients.
Similar proportions of patients received subsequent therapy
in each treatment arm (77% PLD versus 76% trabectedin/PLD),
although platinum-based regimens were slightly less common in
thetrabectedin/PLDarm(49%versus55%:Table1).Detailsforall
ﬁrstsubsequenttherapiesandforﬁrstsubsequentplatinum-based
chemotherapy are given in Tables 2 and 3, respectively. A ﬂow
chart of patients who received platinum as ﬁrst or further
subsequent chemotherapy is provided in Figure 1. A
platinum-based combination regimen was the ﬁrst choice as
Figure 3. Time to subsequent chemotherapy in the overall population (N = 672 patients). (A) All chemotherapy regimens. (B) Platinum-based regimens. C,
number of censored patients; HR, hazard ratio; N, number of patients; P, log-rank test P value; PLD, pegylated liposomal doxorubicin.
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single-agent regimen in 23% (Table 4). Most of ﬁrst subsequent
platinum (81%) was given in combination.
Major subsequent surgery with cytoreductive intent was
performed in 4% PLD versus 6% trabectedin/PLD of the
patients and OS after subsequent surgery was not different (P =
0.4122) by study arm. Subsequent radiation therapy was slightly
more common in the trabectedin/PLD arm (7% versus 4%),
although the types and intent of subsequent radiation therapy
were not consistently collected.
analysis per platinum-sensitivity subsets. Subsequent therapy
and the breakdown of ﬁrst subsequent chemotherapy per
platinum sensitivity subsets are provided in Tables 2 and 4,
respectively. Subsequent platinum-based chemotherapy was
administered to 36% of patients in the stratum of patients with
platinum-resistant disease versus 57% in the partially
platinum-sensitive subset and 64% in the platinum-sensitive
stratum. The proportion of patients treated with subsequent
platinum was similar in the commonly described, discrete
categories of PFI 6–12 versus PFI >12 months, but it showed
a signiﬁcantly increasing trend when PFI was plotted as
a continuous variable (Figure 2).
time to subsequent chemotherapy and survival
all randomized patients. Time to subsequent chemotherapy was
delayed by a median of 2.5 months for patients in the
trabectedin/PLD arm versus those in the PLD arm in the overall
population (Figure 3A). The corresponding median delay was 6
months for subsequent platinum-based chemotherapy (Figure
3B). When only patients who received platinum as subsequent
chemotherapy are analyzed, the difference in median time to
subsequent platinum, i.e. subsequent PFI (sPFI), was 2.7
months: 10.3 months in trabectedin/PLD arm versus 7.6
months in PLD arm; HR = 0.80 (95% conﬁdence interval,
0.64–0.99 P = 0.0361).
The delay in the administration of subsequent platinum does
not appear to have exerted an inﬂuence on OS. Median OS
counted from the administration of subsequent platinum was
identical at 14.9 months in each arm (Figure 4), and 1-year
survival rates were 58% (PLD arm) and 60% (trabectedin/PLD
arm).
Time to subsequent nonplatinum-based chemotherapy (in
patients who only received this type of chemotherapy) as well as
OS counted from the administration of subsequent
nonplatinum-based chemotherapy were similar in each arm
(HR = 0.99 and 0.98, respectively).
analysis per platinum-sensitivity subsets. Subsequent platinum-
based chemotherapy was delayed by a median of 1.9 months
(HR = 0.64; P = 0.0167) for the subset of patients with PFI 6–12
months who were randomly allocated to the trabectedin/PLD
arm. OS counted from the administration of subsequent
platinum was signiﬁcantly extended in these patients, with
a 37% reduction in the risk of death (HR = 0.63; P = 0.0357)
and a 3.5 months longer median OS (13.3 months versus 9.8
months; Figure 5B).
Differences were larger in the PFI 6–12 months subset when
only data of patients who received platinum as ﬁrst subsequent
therapy are analyzed (Figure 6A and B). In this subpopulation,
platinum was delayed a median of 4 months (HR = 0.61; P =
0.0203) and OS from ﬁrst platinum was signiﬁcantly extended
by a median of 8.7 months (HR = 0.54; P = 0.0169).
Delays in the administration of subsequent platinum therapy
for patients randomized to trabectedin/PLD arm versus
PLD alone were shorter in the platinum-resistant stratum
(PFI < 6m o n t h s ;H R= 0.86; P = 0.4854) and in the platinum-
sensitive subset (PFI >12 months; HR = 0.83; P = 0.3017),
Figure 4. Median overall survival from the administration of subsequent platinum-based therapy (all patients who received further platinum; n = 347). C,
number of censored patients; HR, hazard ratio; N, number of patients; P, log-rank test P value; PLD, pegylated liposomal doxorubicin.
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from the administration of subsequent platinum in either subset
(Figure 5A and C).
The observed differences by study arm in time to subsequent
platinum-based chemotherapy (sPFI) and OS outcomes with
subsequent platinum do not appear to be inﬂuenced by patient
baseline characteristics (Table 5).
discussion
OVA-301 was a large randomized trial that evaluated
trabectedin/PLD versus PLD alone in patients with relapsed
ovarian cancer. The trial met its primary end point,
demonstrating signiﬁcantly superior PFS with the combination,
and also showed a positive trend in OS in a protocol-speciﬁed
interim analysis [9, 10]. An analysis of updated OS data,
conducted at the request of regulatory authorities with one
additional year of follow-up, conﬁrmed and strengthened the
survival outcomes previously reported. Compared with PLD
alone, the trabectedin/PLD combination resulted in a 15%
decrease (HR = 0.85, P = 0.092) and a 41% decrease (HR =
0.59, P = 0.0015) in the risk of death in all randomized patients
and in the partially platinum-sensitive subset of patients,
respectively [8, 12].
The present exploratory analyses indicate that the favorable
survival outcomes obtained with trabectedin/PLD combination
over single-agent PLD in OVA-301 cannot be explained by
differences in the extent or nature of subsequent therapies
received by the patients after discontinuing study medication in
this trial. Similar proportions of patients received subsequent
treatments in each arm (77% versus 76%), and indeed
platinum-based regimens were slightly less commonly
administered (49% versus 55%) and prescribed at a later stage
to patients randomly allocated to the arm with the longest
survival (trabectedin/PLD). Although this was a post hoc
analysis, the data (Table 5) demonstrate no major imbalance
between the two treatment arms; any differences in baseline
characteristics in fact favor the PLD alone arm.
The efﬁcacy of platinum rechallenge in relapsed ovarian
cancer has been described as strongly correlated with PFI.
Patients with PFI < 6 months are considered to have platinum-
resistant disease, while patients with PFI ‡ 6 months are
regarded as having platinum-sensitive disease. PFI ‡ 6 months
predicts sensitivity to platinum, although a PFI of 6–12 months
is considered to indicate a partially platinum-sensitive disease.
In this subset of patients, the response rates to further platinum
are lower (25%–30%) compared with those in patients with
PFI > 12 months (up to 60%) [18]. Whether this is a speciﬁc
indication of platinum sensitivity or illustrates a more general
chemosensitivity effect is being a matter of debate [20]. In
OVA-301, subsequent platinum-based chemotherapy was
administered to 52% patients. It is noteworthy that most of
subsequent platinum was administered as a combination
regimen, with a similar proportion between arms: 80% (PLD
arm) and 82% (trabectedin/PLD arm). As expected, the
administration of subsequent platinum to OVA-301 patients
was increasingly more common as their baseline PFI was
longer.
One striking ﬁnding in the OVA-301 trial is the
unexpectedly high proportion of patients with platinum-
resistant disease at baseline in whom a platinum rechallenge
was adopted (86 of 242; 36%). Treatment options for
platinum-resistant patients are limited, and the main goals of
therapy are disease/symptom control and maintenance or
Figure 5. Median overall survival from the administration of subsequent
platinum-based therapy per platinum sensitivity subset (all patients who
received further platinum). (A) Platinum-resistant (PFI < 6 months;
n = 86); (B) Partially platinum sensitive (PFI 6–12 months; n = 121);
(C) Platinum sensitive (PFI > 12 months; n = 139). C, number of censored
patients; HR, hazard ratio; P, log-rank test P value; PLD, pegylated
liposomal doxorubicin.
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a nonplatinum single agent is recommended as the preferred
palliative option [21, 22]. The data in OVA-301 presented
here suggest that, given the poor response induced by the
available cytotoxic agents, patients with platinum-resistant
ovarian cancer are rechallenged with subsequent platinum-
based therapy more often than recommended in the
guidelines. Platinum plus gemcitabine, previously described as
modestly active in platinum-resistant ovarian cancer [23–25],
was administered to 38 of 73 patients (52%) who received
further platinum-based combinations.
Another interesting ﬁnding in the current dataset was that
the proportion of platinum rechallenge in patients with
partially platinum-sensitive disease (57%) was remarkably
similar to that of patients with fully platinum-sensitive disease
(64%). Platinum-based regimens are recommended as standard
second-line therapy in patients with PFI > 12 months, but
beneﬁts of platinum rechallenge in the partially platinum-
sensitive subgroup, with response rates to further platinum of
25%–30%, are less obvious; thus, the recommendation of
platinum rechallenge in this subset is less universal [17]. In
addition, the common occurrence of hypersensitivity reactions
Figure 6. Time to subsequent chemotherapy and median OS from the administration of platinum-based therapy as subsequent line in the platinum-free
interval 6–12 subset. (A) Time to subsequent chemotherapy; (B) Overall survival. C, number of censored patients; HR, hazard ratio; P, log-rank test P value;
PLD, pegylated liposomal doxorubicin; OS, overall survival.
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underlining the need for effective nonplatinum regimens
[20, 26], particularly in the partially platinum-sensitive
population [18, 19]. The current data, obtained from a large
randomized clinical trial conducted in an extensive
geographical area (21 countries from four continents, America,
Asia, Australia and Europe) suggest that platinum rechallenge is
an extended practice in relapsed ovarian cancer patients at all
PFI levels, despite the widespread knowledge of longer PFI
effect on treatment effectiveness [20].
The current hypothesis-generating analyses indicate that the
enhanced survival beneﬁts with trabectedin/PLD over single-
agent PLD in OVA-301, particularly in patients with partially
platinum-sensitive disease, may be due to an extension of the
PFI. It is postulated that treatment of these patients with
trabectedin/PLD, a nonplatinum combination, has
contributed to positive outcomes because of their longer
survival after the start of subsequent platinum-based
chemotherapy. Patients randomly allocated to trabectedin/
PLD received subsequent chemotherapy, including platinum-
based regimens, at a later time than patients in the PLD arm: 6
months for all patients who received subsequent platinum at
any time following OVA-301 trial and 2.7 months for those
patients who received subsequent platinum (3.3 for those in
whom platinum was the ﬁrst option; data not shown). A
provocative ﬁnding in this trial is that OS counted from the
administration of subsequent platinum therapy was
signiﬁcantly prolonged in the partially platinum-sensitive
subset (PFI 6–12 months), possibly by a reversal effect of the
partial resistance pattern in this patient subset [16]. Preclinical
data indicate that the mechanisms underlying resistance to
carboplatin and trabectedin differ in respect of the DNA
repair pathways involved, and this may also partially explain
the superior outcome with platinum-based treatment in
therapy [27]. Delay of platinum re-treatment might
theoretically reduce the effectiveness of such therapy,
particularly if a nonplatinum second-line agent is used
between platinum regimens. However, the majority of
previous reports [13–16, 18, 22, 28] as well as the data in the
current study rather support an increased effectiveness of such
Table 5. Key patient baseline characteristics by platinum-sensitivity subsets in patients with subsequent therapy
All randomized patients with subsequent platinum therapy PLD (n = 183) Trabectedin/PLD (n = 164) Total (N = 347)
Median age (range), years 58 (34–87) 55 (26–82) 56 (26–87)
Performance status (0 versus >0) 62/38 75/25 68/32
Histology (papillary/serous carcinoma)
a 69 67 69
Histology (grade 3) 48 48 48
Previous taxanes 80 75 77
Visceral metastases 41 38 39
Bulky disease 40 41 41
Platinum-resistant subset (PFI < 6 months) PLD (n = 47) Trabectedin/PLD (n = 39) Total (N = 86)
Median age (range), years 56 (34–79) 56 (26–79) 56 (26–79)
Performance status (0 versus >0) 64/36 82/18 72/28
Histology (papillary/serous carcinoma)
a 70 64 67
Histology (grade 3) 47 41 44
Previous taxanes 85 80 83
Visceral metastases 36 31 34
Bulky disease 28 31 29
Partially platinum-sensitive subset (PFI 6–12 months) PLD (n = 52) Trabectedin/PLD (n = 69) Total (N = 121)
Median age (range), years 54 (37–79) 57 (40–76) 56 (37–79)
Performance status (0 versus >0) 64/36 72/28 69/31
Histology (papillary/serous carcinoma)
a 67 72 70
Histology (grade 3) 53 49 50
Previous taxanes 81 71 75
Visceral metastases 42 44 43
Bulky disease 48 39 43
Platinum-sensitive subset (PFI >12 months) PLD (n = 84) Trabectedin/PLD (n = 55) Total (N = 139)
Median age (range), years 59 (34–87) 52 (37–82) 57 (34–87)
Performance status (0 versus >0) 60/40 74/26 66/34
Histology (papillary/serous carcinoma)
a 70 66 68
Histology (grade 3) 45 53 48
Previous taxanes 76 76 76
Visceral metastases 44 36 41
Bulky disease 44 51 47
Data shown are percentages of patients except for age (median and range).
aMost common histological type.
PFI, platinum-free interval; PLD, pegylated liposomal doxorubicin.
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In the platinum-resistant stratum, the lower effect in sPFI
prolongation in the trabectedin/PLD arm (HR = 0.86; P =
0.4854) may be due to the well-established lack of
chemosensitivity in this clinical situation. Results are difﬁcult
to interpret in the platinum-sensitive subset, where a HR of
0.83 (P = 0.3017) was obtained, possibly due, at least in part, to
the immature nature of the data, with a very high proportion of
censoring in this more chemosensitive cohort. A third of these
patients were still alive and they did not yet require subsequent
platinum.
In conclusion, the superior results obtained with trabectedin/
PLD over single-agent PLD in OVA-301 trial cannot be
explained by differences in the extent or nature of subsequent
therapies administered to the patients after completion of on-
study therapy. The current analyses indicate that enhanced
survival with trabectedin/PLD over single-agent PLD in this
trial, particularly in patients with partially platinum-sensitive
disease, may be due to an extension of the PFI coupled with
longer survival after the start of subsequent platinum-based
chemotherapy. A large, randomized prospective clinical trial to
test this hypothesis is in preparation.
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